Advancing peptides for the treatment of rare endocrine and metabolic disorders

We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.

PROGRAMS

AZP-3601

Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.

AZP-3404

AZP-3404 is a first-in-class therapeutic peptide that may restore fat and glucose metabolism in the body.

AZP-3404

LEADERSHIP

Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.

Press Releases & Recent News

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism Download a PDF copy of this …

Read More →
Download a PDF: EN or FR

Amolyt Pharma Announces Research Collaboration with PeptiDream

Amolyt Pharma Announces Research Collaboration with PeptiDream Download a PDF copy of this press release: EN FR Amolyt and Peptidream …

Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top